VIP236 for Advanced Cancer

Recruiting in Palo Alto (17 mi)

+5 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Vincerx Pharma, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer

Research Team

Vincerx Study Director

Principal Investigator

Vincerx Pharma, Inc.

Eligibility Criteria

This trial is for adults over 18 with advanced solid tumors that have not responded to standard treatments. Participants must be able to consent, follow study procedures, and have a performance status showing they can carry out daily activities. They need proper bone marrow, liver, and kidney function.

Inclusion Criteria

My blood, liver, and kidney tests are within normal ranges.

I am 18 or older, can give consent, and will follow the study rules.

I can take care of myself and am up and about more than half of my waking hours.

See 1 more

Exclusion Criteria

I do not have serious heart problems like recent heart attacks or severe chest pain.

I have a history of COPD or other lung problems.

My cancer has spread to my brain, meninges, or spine.

See 1 more

Treatment Details

Interventions

VIP236 (Other)

Trial OverviewThe trial is testing VIP236 as a solo treatment given through the vein (IV) to find the highest dose patients can take without severe side effects. It's for those with advanced cancer who've tried all other options or can't use them.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Dose Escalation of VIP236 (Q3W)Experimental Treatment1 Intervention

Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 of each 21-day cycle

Group II: Dose Escalation of VIP236 (Q2W)Experimental Treatment1 Intervention

Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 and D15 of each 28-day cycle.